GLP-1 Drugs: Unexpected Risks for Chronic Conditions

GLP-1 medications, widely used for type 2 diabetes and obesity, are gaining significant traction, with one in eight Americans reportedly using them by March 2026. While generally considered effective, clinicians emphasize that these drugs may present unforeseen risks for certain patient groups. Notably, the slowing of gastric emptying, a known effect of GLP-1s, can increase the risk of gastroparesis, especially in individuals already prone to digestive motility issues.

Patients with conditions such as Ehlers-Danlos Syndrome (EDS) or Postural Orthostatic Tachycardia Syndrome (PoTS) may be particularly susceptible to these gastrointestinal side effects. Furthermore, the appetite-curbing effects might be problematic for those with chronic conditions who have heightened nutritional needs, such as increased protein and calorie intake to manage inflammation and maintain connective tissue integrity.

Rapid weight loss exceeding one to two pounds per week can lead to loss of lean muscle mass and disrupt electrolyte balance, posing additional concerns for patients with conditions like PoTS. Experts stress the importance of a comprehensive care team, including dietitians and physical therapists, to navigate the use of GLP-1s, especially for individuals with chronic conditions like hEDS. Thorough medical evaluation and individualized treatment decisions are paramount to mitigate risks and ensure optimal outcomes.